Le système RUSH, de l’anglais « Retention using selective hook » est un système développé récemment qui permet d'analyser et de quantifier en temps réel le transport d'une grande diversité de protéines. Le système RUSH permet, grâce à un excès de molécules de Streptavidine (Str.) dirigées dans différents compartiments cellulaires (appelées les hameçons), de retenir des protéines appelées les rapporteurs, comportant un biocapteur fluorescent tel que la GFP (« Green fluorescent protein ») fusionné avec un peptide SBP (« Streptavidin-binding peptide »). L’addition de biotine dans le milieu perturbe l’interaction entre SBP et la Streptavidine, libérant ainsi les rapporteurs de leur hameçon. Basé sur le système RUSH, nous avons établi une méthode de criblage pour identifier des agents pharmacologiques dotés de la capacité à induire la libération d’HMGB1 (« High Mobility Group Box 1 »). La translocation d’HMGB1 depuis le noyau vers le cytoplasme, ainsi que sa sécrétion ou libération passive dans l'espace extracellulaire à travers les membranes plasmiques perméabilisées, représente un signal de danger essentiel à l’activation du système immunitaire. Dans ce système RUSH modifié, une protéine de fusion du Str-NLS3 a été utilisée comme un hameçon nucléaire pour retenir la protéine chimère constituée d'HMGB1, SBP et GFP (HMGB1-SBP-GFP). Lorsque de la biotine est ajoutée en combinaison à des chimiothérapies inductrices de la mort cellulaire immunogène (ICD) telles que les anthracyclines, elle se lie de manière compétitive à Str-NLS3 et permet la libération et la translocation nucléo-cytoplasmique des rapporteurs HMGB1-SBP-GFP. Nous avons utilisé ce système pour des criblages à haut débit visant à identifier des agents induisant le relargage d’HMGB1. Les agents identifiés appartiennent à trois catégories différentes : les inducteurs connus de l’ICD, les inhibiteurs des microtubules et les modificateurs épigénétiques. Leur effet a été confirmé par des méthodes multiples de mesure de la quantité protéique d’HMGB1 nucléaire, cytoplasmique et extracellulaire dans des cellules humaines et murines in vitro ainsi que dans le plasma de souris. Nos données révèlent également que ces agents induisent la libération d’HMGB1 par des mécanismes distincts : arrêt du cycle cellulaire, acétylation des histones ou effets « on-target » par l'inhibition d’ADN méthyltransférase. Il serait alors intéressant d'étudier si les effets décrits ici peuvent contribuer aux effets immunostimulateurs des médicaments utilisés pour le traitement de cancers ou de maladies parasitaires.Le système RUSH permettant la synchronisation et la quantification de la sécrétion des protéines du réticulum endoplasmique (RE) vers l'appareil de Golgi, il permet de cribler un grand nombre de composés afin d’identifier des inhibiteurs des sécrétions candidates. Nous avons conçu et construit une lignée cellulaire humaine exprimant les chimères SBP-GFP sécrétables ainsi que les hameçons Str-KDEL ciblant l’ER ; la biotine permet donc la libération du rapporteur par les voies de sécrétion classiques. Nous avons identifié et validé plusieurs médicaments qui sont capables d’inhiber la sécrétion de protéines : les anti-angineux, les antidépresseurs, les anti-helminthiques, anti-psychotiques, anti-protozoaires, et agents immunosuppresseurs. Ces composés varient dans leur capacité à inhiber la synthèse des protéines et de compromettre la morphologie du RE ou l'intégrité du Golgi. Les données ont ensuite été soumises à une analyse bio-informatique et cette procédure a permis l'identification de quatre groupes en fonction de leur mode d'action. Cette partie démontre la faisabilité et l'utilité d'un nouvel essai de criblage phénotypique basé sur le système RUSH. Nous avons conçu des systèmes de HSC (« High Content Screening ») basés sur le système RUSH, qui ont permis l'identification d'agents pharmacologiques induisant la libération d’HMGB1, ainsi que des inhibiteurs de la sécrétion protéique. / The retention using selective hooks (RUSH) system allows withholding load cargoes with fluorescent biosensor such as green fluorescent proteins (GFP) fused to a streptavidin-binding peptide (SBP) by an excess of streptavidin (Str) molecules that are addressed to different subcellular localizations. Addition of biotin competitively disrupts this interaction, liberating the reporter from its hook. Based on the RUSH system, we developed a screening assay to identify pharmacological agents endowed with HMGB1 (high mobility group box 1) releasing capacities. The translocation of HMGB1 from the nucleus to the cytoplasm and its secretion or passive release through the permeabilized plasma membrane constitutes a major cellular danger signal. Extracellular HMGB1 can interact with specific pattern recognition receptors to stimulate pro-inflammatory and immunostimulatory pathways. In this modified RUSH system, a Str-NLS3 fusion protein was used as a nuclear hook to seize SBP fused with HMGB1 and GFP. When combined with biotin, which competitively binds to Stre-NLS3 to free the HMGB1-SBP-GFP, immunogenic cell death (ICD) inducers such as anthracyclines were able to cause the nucleo-cytoplasmic translocation of HMGB1-SBP-GFP. We used this system for high-content screenings (HCS) to identify HMGB1 releasing agents. Hits fell into three functional categories: known ICD inducers, microtubule inhibitors, and epigenetic modifiers. Their effective action was confirmed by multiple methods monitoring nuclear, cytoplasmic and extracellular HMGB1 pools, both in cultured human or murine cells, as well as in mouse plasma. These agents induced HMGB1 release through a whole set of distinct mechanisms, cell cycle arrest, histone acetylation, or on-target effect. It will be interesting to learn whether such effects may contribute to the immunostimulatory effects of drugs that are used to treat malignant disease or worm infection. For HCS of identification of pharmacological inhibitors of conventional protein secretion, we constructed a human cell line co-expressing soluble secretory-SBP-GFP (ss-SBP-GFP) and Str-KDEL hook within the endoplasmic reticulum (ER) lumen, and biotin addition releases the reporter, ss-SBP-GFP via the conventional Golgi-dependent protein secretion pathway into the culture supernatant. We identified and validated a series of molecularly unrelated drugs including antianginal, antidepressant, anthelmintic, antipsychotic, antiprotozoal and immunosuppressive agents that inhibit protein secretion. These compounds vary in their capacity to suppress protein synthesis and to compromise ER morphology and Golgi integrity, as well as in the degree of reversibility of such effects. These data was then subjected to bioinformatics analysis including correlation analyses, non-supervised hierarchical clustering, and principal component analysis and led to the identification of 4 clusters of agents. We demonstrate the feasibility and utility of a novel RUSH-based phenotypic screening assay. In summary, we built HCS systems based on the improved RUSH sysytem for identification of agents that induce HMGB1 release or inhibit conventional protein secretion.

No description available.

Malaria, caused by the parasite Plasmodium falciparum, has a long history as a global health threat. The vector-borne disease causes millions of deaths yearly, especially in developing countries with tropical climates that facilitate transmission. Compounding the problem is the emergence of drug-resistant strains due to overuse of outdated treatments. New compounds with antiplasmodial activity are needed to be developed as effective drugs against malaria. The hypothesis for this project is that marine microorganisms have a high likelihood of yielding novel antiplasmodial chemotypes because of their high diversity, which has not yet been explored for antimalarial development. In this project, microbes harvested and fermented by the Harbor Branch Oceanographic Institute in Fort Pierce, Florida were explored as sources for antiplasmodial natural products. Using a SYBR Green I fluorescence-based assay, 1,000 microbial extracts were screened for inhibition of the multidrug-resistant Plasmodium falciparum strain Dd2. Dose-response analysis was performed on 46 fractions from isolates whose extracts demonstrated greater-than or equal to] 70% inhibition of Dd2 at 1 micro]g/mL. To evaluate cytotoxicity, the MTS cell viability assay was used to calculate IC50 of extracts from active isolates in NIH/3T3 embryonic mouse fibroblasts. Several extracts demonstrated low IC50 in Dd2 and high IC50 in 3T3, suggesting that they contain potential lead antimalarial compounds. Extracts with high selectivity indices (potent plasmodial inhibition with low mammalian toxicity) have been prioritized for dereplication, with the goal of identifying novel active components that can be developed as antimalarial drugs.

Tuberculosis (TB) is a respiratory disease caused by Mycobacterium tuberculosis (Mtb) that kills around 1.3 million people annually. Multi-drug resistant TB (MDR-TB) strains are increasingly encountered, in part resulting from shortcomings of current TB drug regimens that last between six to nine months. Patients may stop taking the antibiotics during their allotted regimen, leading to drug resistant TB strains. Novel drug screening platforms are therefore necessary to find drugs effective against MDR-TB. In order to discover compounds that target under-exploited pathways that may be essential only in vivo, the proposed screening platform will use a novel approach to drug discovery by blocking essential protein-protein interactions (PPI). In Mtb, PPI can be monitored by mycobacterial protein fragment complementation (M-PFC). This project will re-engineer the M-PFC assay to include the red fluorescent mCherry reporter for increased efficiency and sensitivity in high-throughput screening applications. To optimize the mCherry assay, we have developed fluorescent M-PFC reporter strains to monitor distinct PPI required for Mtb virulence: homodimerization of the dormancy regulator DosR. A drug screen will then identify novel compounds that inhibit this essential PPI. The screen will involve positional-scanning combinatorial synthetic libraries, which are made up of chemical compounds with varying side chains. This work will develop novel tools for TB drug discovery that could identify new treatments for the emerging world threat of MDR-TB.

No description available.

Cancer progression is accompanied with alterations in the cell biomechanical phenotype, including changes in cell structure, morphology, and responses to microenvironmental stress. These alterations result in an increased deformability of transformed cells and reduced resistance to mechanical stimuli, enabling motility and invasion. Therefore, single cell biomechanical properties could be served as a powerful label-free biomarker for effective characterization and early detection of single cancer cells. Advances and innovations in microsystems and nanotechnology have facilitated interrogation of the biomechanical properties of single cells to predict their tumorigenicity, metastatic potential, and health state. This dissertation utilized Atomic Force Microscopy (AFM) for the cell biomechanical phenotyping for cancer diagnosis and early detection, efficacy screening of potential chemotherapeutic agents, and also cancer stem-like/tumor initiating cells (CSC/TICs) characterization as the critical topics received intensive attention in the search for effective cancer treatment. Our findings demonstrated the capability of exogenous sphingosine to revert the aberrant biomechanics of aggressive cells and showed a unique, mechanically homogeneous, and extremely soft characteristic of CSC/TICs, suitable for their targeted isolation. To make full use of cell biomechanical cues, this dissertation also considered the application of nonlinear viscoelastic models such as Fractional Zener and Generalized Maxwell models for the naturally complex, heterogeneous, and nonlinear structure of living cells. The emerging need for a high-throughput clinically relevant alternative for evaluating biomechanics of individual cells led us to the development of a microfluidic system. Therefore, a high-throughput, label-free, automated microfluidic chip was developed to investigate the biophysical (biomechanical-bioelectrical) markers of normal and malignant cells. Most importantly, this dissertation also explored the biomechanical response of cells upon a dynamic loading instead of a typical transient stress. Notably, metastatic and non-metastatic cells subjected to a pulsed stress regimen exerted by AFM exhibited distinct biomechanical responses. While non-metastatic cells showed an increase in their resistance against deformation and resulted in strain-stiffening behavior, metastatic cells responded by losing their resistance and yielded slight strain-softening. Ultimately, a second generation microfluidic chip called an iterative mechanical characteristics (iMECH) analyzer consisting of a series of constriction channels for simulating the dynamic stress paradigm was developed which could reproduce the same stiffening/softening trends of non-metastatic and metastatic cells, respectively. Therefore, for the first time, the use of dynamic loading paradigm to evaluate cell biomechanical responses was used as a new signature to predict malignancy or normalcy at a single-cell level with a high (~95%) confidence level. / Ph. D.

O uso da LDE como veículo para quimioterápicos tem mostrado ser uma boa estratégia para aumentar a eficácia terapêutica dos mesmos. Nesse estudo, a LDE foi empregada como veículo para um derivado lipofílico do metotrexato (MTX), o di-dodecil metotrexato, que foi obtido com rendimento elevado através de reação de esterificação do MTX. O aumento na lipofilicidade do derivado possibilitou incorporação na LDE com rendimento e estabilidade elevados. O IC50 de LDE-di-dodecil MTX foi cerca de 100 vezes menor em relação ao MTX comercial, sua captação celular mais elevada nas linhagens leucêmicas estudadas e sua toxicidade animal reduzida, mostrando que a LDE é um veículo promissor para este fármaco. / The use of LDE as vehicle to drugs is a great strategy to improve the therapeutic index and reduce the side effects. In this study LDE was used as vehicle to di-dodecyl methotrexate, a lipophilic derivative of MTX, obtained through an esterification reaction with a high yield. The increased lipophilicity of the derivative allowed a high association to LDE and good stability. The IC50 of LDE-di-dodecyl MTX was lower than that of the MTX and the uptake was higher in leukemic cells. The MTX toxicity in mice was reduced after association to LDE, showing that LDE is a promising vehicle to this drug.

Bakgrund: Barn och ungdomar inom barn- och ungdomspsykiatrisk öppenvård testas för droganvändning genom övervakat urinprov av en sjuksköterska antingen slumpmässigt eller i samband med introduktion av behandling med läkemedel eller utredning. Det finns sparsam vetenskaplig kunskap kring detta ämne från ett sjuksköterskeperspektiv och inte alls från barnens perspektiv.  Enligt socialstyrelsens riktlinjer för missbruk och droger finns det risk att man utför övervakat urinprov slentrianmässigt då det kan bli en rutin som används utan reflektion.  Syfte: Syftet med denna studie är att belysa sjuksköterskors erfarenheter kring övervakat urinprov av ungdomar inom barn och ungdomspsykiatrisk öppenvård. Metod: En kvalitativ intervjustudie med ett induktivt förhållningssätt har använts. Åtta sjuksköterskor från barn och ungdomspsykiatrisk öppenvård har ingått i studien. Materialet transkriberades och analyserades i enlighet med Graneheim och Lundman (2004) genom konventionell innehållsanalys. Dessutom diskuteras metodvalet utifrån Graneheim, Lindgren och Lundman (2017) för att öka trovärdigheten. Resultat: Detta i tre slutkategorier; Att två världar krockar, Att individanpassa utefter behov och relation, Att bli inspirerad och motiverad av patienter och föräldrar. Konklusion: Sjuksköterskor som har erfarenheter av övervakat urinprov träffar patienter på olika sätt, ibland planerat där en relation finns och man har ett omvårdnadsperspektiv men ibland där man träffar ungdomen på ordination av annan behandlare enbart för att utföra en åtgärd. Det finns rutiner som man skall följa i samband med ett övervakat urinprov men vi kan konkludera att det sker anpassningar utifrån att bevara ungdomens integritet. Vi kan också konstatera att sjuksköterskorna motiveras av att arbeta med barn och ungdomar och deras familjer och verkar trivas bäst där det finns utrymme för att skapa relationer och tillit med patienterna

Separation technologies have occupied a central role in the current practices of analytical methods used for drug analysis today. As the emphasis in contemporary drug analysis shifts towards ultra-trace concentrations, the contribution from unwanted matrix interferences takes on greater significance. In order to single out a trace substance with confidence from a rapidly expanding list of drug compounds (and their metabolites) in real complex specimens, analytical technologies must evolve to keep up with such trends. Today, the task of unambiguous identification in forensic toxicology still relies heavily upon chromatographic methods based on mass spectrometric detection, in particular GC-MS in electron ionisation (EI) mode. Although the combined informing power of (EI) GC-MS has served faithfully in a myriad of drug application studies to date, we may ask if (EI) GC-MS will remain competitive in meeting the impending needs of ultra-trace drug analysis in the fut ure? To what extent of reliability can sample clean-up strategies be used in ultra-trace analysis without risking the loss of important analytes of interest? The increasing use of tandem mass spectrometry with one-dimensional (1D) chromatographic techniques (e.g. GC-MS/MS) at its simplest, considers that single-column chromatographic analysis with mass spectrometry alone is not sufficient in providing unambiguous confirmation of the identity of any given peak, particularly when there are peak-overlap. Where the mass spectra of the individual overlapping peaks are highly similar, confounding interpretation of their identities may arise. By introducing an additional resolution element in the chromatographic domain of a 1D chromatographic system, the informing power of the analytical system can also be effectively raised by the boost in resolving power from two chromatographic elements. Thus this thesis sets out to address the analytical challenges of modern drug analysis through the application of high resolut ion comprehensive two-dimensional gas chromatography (GC„eGC) to a series of representative drug studies of relevance to forensic sciences.

In 2001 the human proteome organization (HUPO) was created with the ambition to identify and characterize all proteins encoded in the human genome according to several criteria; their expression levels in different tissues and under different conditions; the sub-cellular localization; post-translational modifications; interactions, and if possible also the relationship between their structure and function.When the knowledge of different proteins and their potential interactions increases, so does the need for methods able to unravel the nature of molecular processes in cells and organized tissues, and ultimately for clinical use in samples obtained from patients. The in situ proximity ligation assay (in situ PLA) was developed to provide localized detection of proteins, post-translational modifications and protein-protein interactions in fixed cells and tissues. Dual recognition of the target or interacting targets is a prerequisite for the creation of a circular reporter DNA molecule, which subsequently is locally amplified for visualization of individual protein molecules in single cells. These features offer the high sensitivity and selectivity required for detection of even rare target molecules. Herein in situ PLA was first established and then employed as a tool for detection of both interactions and post-translational modifications in cultured cells and tissue samples. In situ PLA was also adapted to high content screening (HCS) for therapeutic effects, where it was applied for cell-based drug screening of inhibitors influencing post-translational modifications. This was performed using primary cells, paving the way for evaluation of drug effects on cells from patient as a diagnostic tool in personalized medicine. In conclusion, this thesis describes the development and applications of in situ PLA as a tool to study proteins, post-translational modifications and protein-protein interactions in genetically unmodified cells and tissues, and for clinical interactomics.